Advanced search
Start date

Study of metformin effects in mTOR/S6Ks signal transduction pathway in lung cancer cells

Grant number: 16/02483-7
Support type:Scholarships in Brazil - Scientific Initiation
Effective date (Start): April 01, 2016
Effective date (End): February 28, 2017
Field of knowledge:Health Sciences - Nutrition - Nutrition Biochemistry
Principal Investigator:Fernando Moreira Simabuco
Grantee:Ana Paula Morelli
Home Institution: Faculdade de Ciências Aplicadas (FCA). Universidade Estadual de Campinas (UNICAMP). Limeira , SP, Brazil
Associated research grant:12/13558-7 - Molecular characterization of S6Ks in obesity and its associated diseases, AP.JP


Over the past few years, the mTOR signal transduction pathway has been associated to the control of energy balance of the body, acting either as a sensor of the amount of available nutrients or as a trigger for the expense or storage of energy. The S6Ks proteins have shown an important role in the mTOR signaling, functioning as effectors of this signaling pathway, although still having open questions. Among the diseases related to obesity, as well as to the control or dysfunction of mTOR/S6Ks pathway, one may highlight cancer, whose incidence in obese is clearly higher. Metformin has been used in the treatment of type II diabetes, but many reports in the literature indicate its important role in the fight against cancer (Kasznicki et al, 2014. Wang et al, 2015.). This research project aims to study the effects of metformin treatment on the mTOR/S6Ks signaling transduction pathway in lung cancer cells. For this purpose, A549 lung cancer cells will be subjected to treatment with metformin and a proteomic analysis will be performed from total protein extracts, using the labeling known as SILAC (Stable Isotope Labeling by Amino acids in Cell culture). We expect to find effects in the modulation of several signaling pathways by comparing cells treated with metformin and control cells, including components of the mTOR pathway, such as S6Ks proteins. (AU)